{
    "Trade/Device Name(s)": [
        "INFINITI 2C9 & VKORC1 Multiplex Assay for Warfarin"
    ],
    "Submitter Information": "AutoGenomics, Inc.",
    "510(k) Number": "K073014",
    "Predicate Device Reference 510(k) Number(s)": [
        "K043576",
        "K060564"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "ODW",
        "ODV",
        "NSU"
    ],
    "Summary Letter Date": "January 28, 2008",
    "Summary Letter Received Date": "October 29, 2007",
    "Submission Date": "October 23, 2007",
    "Regulation Number(s)": [
        "21CFR862.3360",
        "21CFR864.7750",
        "21CFR862.2570"
    ],
    "Regulation Name(s)": [
        "Drug metabolizing enzyme genotyping system",
        "Prothrombin Time Test",
        "Instrumentation for Clinical Multiplex Test System"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "toxicology"
    ],
    "Analyte(s)": [
        "CYP4502C9 *2",
        "CYP4502C9 *3",
        "VKORC1 3673 (-1639)"
    ],
    "Specimen Type(s)": [
        "Whole Blood",
        "Purified DNA from whole blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "AutoGenomics INFINITI Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Microarray-based genotyping",
        "PCR amplification",
        "Allele specific primer extension",
        "DNA hybridization",
        "Confocal microscopy"
    ],
    "Methodologies": [
        "Genotyping",
        "Molecular genetic testing",
        "PCR",
        "Microarray"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Microarray",
        "Software",
        "Amplification kit"
    ],
    "Document Summary": "FDA 510(k) summary for INFINITI 2C9 & VKORC1 Multiplex Assay for Warfarin, a microarray-based genetic test for CYP4502C9 and VKORC1 variants related to warfarin sensitivity.",
    "Indications for Use Summary": "Qualitative genetic test to detect CYP4502C9 *2, *3 and VKORC1 3673 (-1639) variants in DNA from EDTA-anticoagulated whole blood to identify individuals at risk for sensitivity to warfarin.",
    "fda_folder": "Toxicology"
}